{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:35:40Z","timestamp":1781782540511,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T00:00:00Z","timestamp":1450742400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00280-015-2940-3","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T12:01:56Z","timestamp":1450785716000},"page":"653-657","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy"],"prefix":"10.1007","volume":"77","author":[{"given":"Alessia","family":"Dalla Pria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Bendle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Ramaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Boffito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,22]]},"reference":[{"issue":"5","key":"2940_CR1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<645::AID-IJC6>3.0.CO;2-X","volume":"73","author":"TR Cote","year":"1997","unstructured":"Cote TR, Biggar RJ, Rosenberg PS, Devesa SS, Percy C, Yellin FJ, Lemp G, Hardy C, Geodert JJ, Blattner WA (1997) Non-Hodgkin\u2019s lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS\/Cancer Study Group. Int J Cancer 73(5):645\u2013650","journal-title":"Int J Cancer"},{"issue":"12","key":"2940_CR2","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/jnci\/djm010","volume":"99","author":"RJ Biggar","year":"2007","unstructured":"Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA (2007) AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 99(12):962\u2013972. doi: 10.1093\/jnci\/djm010","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2940_CR3","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","volume":"112","author":"GM Mead","year":"2008","unstructured":"Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, Clawson SM, Stenning SP, Yule CL, Jack AS (2008) A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial). Blood 112(6):2248\u20132260. doi: 10.1182\/blood-2008-03-145128","journal-title":"Blood"},{"issue":"1","key":"2940_CR4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncr.23522","volume":"113","author":"A Oriol","year":"2008","unstructured":"Oriol A, Ribera JM, Bergua J, Gimenez Mesa E, Grande C, Esteve J, Brunet S, Moreno MJ, Escoda L, Hernandez-Rivas JM, Hoelzer D (2008) High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer 113(1):117\u2013125. doi: 10.1002\/cncr.23522","journal-title":"Cancer"},{"issue":"8","key":"2940_CR5","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","volume":"22","author":"JA Barnes","year":"2011","unstructured":"Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, Hochberg EP, Abramson JS (2011) Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt\u2019s lymphoma: a retrospective analysis. Ann Oncol 22(8):1859\u20131864. doi: 10.1093\/annonc\/mdq677","journal-title":"Ann Oncol"},{"issue":"8","key":"2940_CR6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/QAD.0000000000000623","volume":"29","author":"F Alwan","year":"2015","unstructured":"Alwan F, He A, Montoto S, Kassam S, Mee M, Burns F, Edwards S, Wilson A, Tenant-Flowers M, Marcus R, Ardeshna KM, Bower M, Cwynarski K (2015) Adding rituximab to CODOX-M\/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy. AIDS 29(8):903\u2013910. doi: 10.1097\/QAD.0000000000000623","journal-title":"AIDS"},{"issue":"9","key":"2940_CR7","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2004-05-1747","volume":"104","author":"M Bower","year":"2004","unstructured":"Bower M, McCall-Peat N, Ryan N, Davies L, Young AM, Gupta S, Nelson M, Gazzard B, Stebbing J (2004) Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 104(9):2943\u20132946","journal-title":"Blood"},{"issue":"9","key":"2940_CR8","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1002\/jps.22655","volume":"100","author":"L Griffin","year":"2011","unstructured":"Griffin L, Annaert P, Brouwer KL (2011) Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J Pharm Sci 100(9):3636\u20133654. doi: 10.1002\/jps.22655","journal-title":"J Pharm Sci"},{"issue":"3","key":"2940_CR9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF00262421","volume":"3","author":"S Monjanel","year":"1979","unstructured":"Monjanel S, Rigault JP, Cano JP, Carcassonne Y, Favre R (1979) High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach. Cancer Chemother Pharmacol 3(3):189\u2013196","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2940_CR10","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1046\/j.1523-1755.2001.0600031058.x","volume":"60","author":"A Takeuchi","year":"2001","unstructured":"Takeuchi A, Masuda S, Saito H, Doi T, Inui K (2001) Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. Kidney Int 60(3):1058\u20131068. doi: 10.1046\/j.1523-1755.2001.0600031058.x","journal-title":"Kidney Int"},{"issue":"5","key":"2940_CR11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/14737175.6.5.635","volume":"6","author":"MR Green","year":"2006","unstructured":"Green MR, Chowdhary S, Lombardi KM, Chalmers LM, Chamberlain M (2006) Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma. Expert Rev Neurother 6(5):635\u2013652. doi: 10.1586\/14737175.6.5.635","journal-title":"Expert Rev Neurother"},{"issue":"8483","key":"2940_CR12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(86)91123-2","volume":"1","author":"CJ Twelves","year":"1986","unstructured":"Twelves CJ (1986) Folinic acid rescue and methotrexate toxicity. Lancet 1(8483):737","journal-title":"Lancet"},{"issue":"3","key":"2940_CR13","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000189111","volume":"73","author":"MG El-Badawi","year":"1996","unstructured":"El-Badawi MG, Abdalla MA, Bahakim HM, Fadel RA (1996) Nephrotoxicity of low-dose methotrexate in guinea pigs: an ultrastructural study. Nephron 73(3):462\u2013466","journal-title":"Nephron"},{"issue":"1","key":"2940_CR14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/0366-6999.147829","volume":"128","author":"W Zhang","year":"2015","unstructured":"Zhang W, Zhang Q, Tian X, Zhao H, Lu W, Zhen J, Niu X (2015) Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution. Chin Med J (Engl) 128(1):111\u2013118. doi: 10.4103\/0366-6999.147829","journal-title":"Chin Med J (Engl)"},{"issue":"26","key":"2940_CR15","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1182\/blood-2013-01-480335","volume":"121","author":"S Radtke","year":"2013","unstructured":"Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, Moricke A, Stanulla M, Schrappe M, Langer T (2013) Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 121(26):5145\u20135153. doi: 10.1182\/blood-2013-01-480335","journal-title":"Blood"},{"issue":"3","key":"2940_CR16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/annonc\/mdi075","volume":"16","author":"K Jahnke","year":"2005","unstructured":"Jahnke K, Korfel A, Martus P, Weller M, Herrlinger U, Schmittel A, Fischer L, Thiel E (2005) High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 16(3):445\u2013449. doi: 10.1093\/annonc\/mdi075","journal-title":"Ann Oncol"},{"issue":"9","key":"2940_CR17","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/infdis\/jit043","volume":"207","author":"L Ryom","year":"2013","unstructured":"Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD (2013) Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A: D study. J Infect Dis 207(9):1359\u20131369. doi: 10.1093\/infdis\/jit043","journal-title":"J Infect Dis"},{"issue":"6","key":"2940_CR18","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/labinvest.2011.48","volume":"91","author":"JJ Kohler","year":"2011","unstructured":"Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, Russ R, Santoianni R, Lewis W (2011) Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 91(6):852\u2013858. doi: 10.1038\/labinvest.2011.48","journal-title":"Lab Invest"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2940-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2940-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2940-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T19:07:20Z","timestamp":1553627240000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2940-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,22]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["2940"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2940-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,22]]}}}